Implications of Cancer Staging Uncertainties in Radiation Therapy Decisions
暂无分享,去创建一个
Peter Dunscombe | Chris Newcomb | Robert C. Lee | Edidiong Ekaette | Peter Craighead | Karie-Lynn Kelly | P. Dunscombe | C. Newcomb | E. Ekaette | K.-L. Kelly | P. Craighead | Karie-Lynn Kelly
[1] A. Vecchione,et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. , 1999, Anticancer research.
[2] M. Laberge. [Cancer of the breast]. , 1961, Laval medical.
[3] B Padovani,et al. Etiologic diagnosis of hepatic lesions in cancer patients. Value of ultrasound and liver function tests. , 1997, Clinical imaging.
[4] B J McNeil,et al. Computed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison. , 1983, Radiology.
[5] Louis Anthony Cox,et al. Risk Analysis Foundations, Models, and Methods , 2001 .
[6] W. D. Bostick,et al. Biological markers as an aid in the clinical management of patients with liver metastases , 1982, Journal of surgical oncology.
[7] A P Forrest,et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. , 1996, Lancet.
[8] S. Yasuda,et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy , 2001, Nuclear medicine communications.
[9] Ralph L. Keeney,et al. Value-Focused Thinking: A Path to Creative Decisionmaking , 1992 .
[10] D. Theodorescu,et al. Impact of second opinion pathology in the definitive management of patients with bladder carcinoma , 2001, Cancer.
[11] R C Lee,et al. 221 DEVELOPMENT OF HUMAN EXPOSURE-FACTOR DISTRIBUTIONS USING MAXIMUM-ENTROPY INFERENCE , 1995 .
[12] G J Rosenbusch,et al. [Reliability of sonography in diagnosing liver metastases in breast and bronchial cancer. A retrospective comparison of physical examination, laboratory tests and liver scintigraphy]. , 1986, Ultraschall in der Medizin.
[13] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .
[14] Gisela del Rocío Estrada-Sánchez,et al. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases]. , 2003, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
[15] A. Lluch,et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis , 2005, Breast Cancer Research and Treatment.
[16] Gisela del Rocío Estrada Sánchez,et al. Confiabilidad del CA 15-3 como seguimiento en las pacientes con carcinoma mamario y metástasis óseas , 2003 .
[17] E T BELL,et al. The Diseases of the Breast , 1925, Nature.
[18] R. Sirota,et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome , 2000, Cancer.
[19] A. C. Lind,et al. Prospective peer review in surgical pathology. , 1995, American journal of clinical pathology.
[20] Norman Wolmark,et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J Hermans,et al. Prospective comparative study of ultrasound, CT-scan, scintigraphy and laboratory tests to detect hepatic metastases. , 1991, Journal of nuclear biology and medicine.
[22] J O Prior,et al. The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer , 2003, Nuclear medicine communications.
[23] M. Weinstein,et al. Clinical Decision Analysis , 1980 .
[24] W. H. M. Schattevoet,et al. Die Zuverlässigkeit der Sonographie bei der Diagnostik von Lebermetastasen beim Mamma- und Bronchialkarzinom , 2008 .
[25] D. Carlow. Status report. Canadian association of provincial cancer agencies. , 2000, Chronic diseases in Canada.
[26] F. J. Davis,et al. Illustration of Sampling‐Based Methods for Uncertainty and Sensitivity Analysis , 2002, Risk analysis : an official publication of the Society for Risk Analysis.
[27] A. Ramsay,et al. The Clinicopathological Meeting: A Means of Auditing Diagnostic Performance , 1993, The American journal of surgical pathology.
[28] G. Fuller,et al. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice , 1997, Cancer.
[29] M Torres,et al. CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA , 1995, The International journal of biological markers.
[30] W. Westra,et al. The impact of second opinion surgical pathology on the practice of head and neck surgery: A decade experience at a large referral hospital , 2002, Head & neck.
[31] C A Williams,et al. The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] T. Mcgarrity,et al. An analysis of imaging studies and liver function tests to detect hepatic neoplasia , 1987, Digestive Diseases and Sciences.
[33] P. Ferrari,et al. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy , 1999, British Journal of Cancer.
[34] Ross D. Shachter,et al. Representation and Analysis of Medical Decision Problems with Influence Diagrams , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[35] Jong-Hyeon Jeong,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002, The New England journal of medicine.
[36] L. Frati,et al. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer , 1995, The International journal of biological markers.
[37] D. Elder,et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. , 2002, Archives of dermatology.
[38] Max Henrion,et al. Uncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis , 1990 .
[39] M. Hou,et al. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. , 1999, The Kaohsiung journal of medical sciences.
[40] Monica Morrow,et al. Changes in breast cancer therapy because of pathology second opinions , 2002, Annals of Surgical Oncology.
[41] R. Nakhleh,et al. Amended reports in surgical pathology and implications for diagnostic error detection and avoidance: a College of American Pathologists Q-probes study of 1,667,547 accessioned cases in 359 laboratories. , 1998, Archives of pathology & laboratory medicine.
[42] P. Ferrari,et al. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer , 2000, British Journal of Cancer.
[43] David C. Smith,et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial , 1996, The Lancet.
[44] Z Kusić,et al. Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. , 1999, Nuclear medicine communications.
[45] W. Yasmineh,et al. Value of alkaline phosphatase, 5'-nucleotidase, gamma-glutamyltransferase, and glutamate dehydrogenase activity measurements (single and combined) in serum in diagnosis of metastasis to the liver. , 1977, Clinical chemistry.
[46] Hans-Jürgen Gallowitsch,et al. F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast Carcinoma: A Comparison to Conventional Imaging , 2003, Investigative radiology.
[47] A. Y. Foo,et al. Measurement of biliary alkaline phosphatase by mini-column chromatography and by electrophoresis and its application to the detection of liver metastases in patients with breast cancer. , 1984, Journal of clinical pathology.
[48] M. Brandeau,et al. Operations research and health care : a handbook of methods and applications , 2004 .
[49] J. Grieve,et al. Quality Assurance of Histopathologic Diagnosis in the British Army: Role of the Army Histopathology Registry in Completed Case Review , 1986, Journal of the Royal Army Medical Corps.
[50] J Hermans,et al. Hepatic metastases: comparative study of diagnostic ultrasound, CT, nuclear scintigraphy and laboratory tests. , 1991, The Netherlands journal of surgery.
[51] A Pupi,et al. Staging Breast Cancer - Screening for Occult Metastases , 1985, Tumori.
[52] E. Imhoff,et al. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer , 2004, European Radiology.
[53] Fiorella Guadagni,et al. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer , 2001, Breast Cancer Research and Treatment.
[54] D. Miller,et al. Pathology Slide Review in Gynecologic Oncology , 1998, Obstetrics and gynecology.
[55] M Untch,et al. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases. , 1998, Anticancer research.
[56] Averill M. Law,et al. Simulation Modeling and Analysis , 1982 .
[57] K. Holli,et al. Role of Chest X-ray in Diagnosis of the First Breast Cancer Relapse: A Randomized Trial , 2003, Breast Cancer Research and Treatment.
[58] M. Góralczyk,et al. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases]. , 2001, Przeglad lekarski.
[59] Dino Amadori,et al. Staging of Breast Cancer: New Recommended Standard Procedure , 2002, Breast Cancer Research and Treatment.
[60] D K Owens,et al. Use of Influence Diagrams to Structure Medical Decisions , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[61] F. Guadagni,et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.